OLDAKOWSKI JOSEPH FRANK sold $15K of CLOV

OLDAKOWSKI JOSEPH FRANK (VP OF FINANCE AND CONTROLLER) sold 3,170 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.64 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · OLDAKOWSKI JOSEPH FRANK
Published Sep 17, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to affect market perception of Clover Health.

02

Market read

A small insider sell with no immediate price impact; primarily of interest to compliance and monitoring teams.

03

What to watch

Potential future dilution from upcoming financing rounds could make the current stake less significant.

Relevance 2/10Novelty 3/10Timing: post‑market 2026‑09‑16 filing

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑scheduled trades.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

VP of Finance sold 3,170 shares for $14.7K via a 10b5‑1 plan, reducing his stake to 275,897 shares.

Expected impact

No material price impact expected.

Evidence & confidence

The sale size is small relative to float and disclosed under a pre‑arranged plan, indicating routine portfolio rebalancing rather than loss of confidence.

Market effects

None; the transaction is company‑specific and does not affect the health‑tech sector.

None; Clover Health trades on US exchanges only.

None; the sale is too small to influence broader markets.

Counterpoint

If the insider had insider knowledge of upcoming negative news, the sale could be a warning sign, but the 10b5‑1 plan weakens that argument.

Key entities

  • Clover Health Investments, Corp.

    US‑listed health‑tech firm (ticker CLOV).

  • Joseph Frank Oldakowski

    Vice President of Finance and Controller, insider reporter.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.